Innovus Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:INNV)

$0.10 0.01 (11.49 %)
(As of 11/21/2017 08:41 AM ET)
Previous Close$0.09
Today's Range$0.09 - $0.10
52-Week Range$0.08 - $0.39
Volume3.37 million shs
Average Volume746,776 shs
Market Capitalization$14.39 million
P/E RatioN/A
Dividend YieldN/A
Beta4.14

About Innovus Pharmaceuticals (OTCMKTS:INNV)

Innovus Pharmaceuticals logoInnovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.


Industry, Sector and Symbol:
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: OTCMKTS:INNV
  • Previous Symbol: NASDAQ:INNV
  • CUSIP: N/A
  • Web: www.innovuspharma.com
Debt:
  • Current Ratio: 0.64%
  • Quick Ratio: 0.46%
Sales & Book Value:
  • Annual Sales: $4.82 million
  • Price / Sales: 3.31
  • Book Value: $0.01 per share
  • Price / Book: 9.70
Profitability:
  • Trailing EPS: ($0.07)
  • Net Income: $-13,700,000.00
  • Net Margins: -102.95%
  • Return on Equity: -330.39%
  • Return on Assets: -72.75%
Misc:
  • Employees: 5
  • Outstanding Shares: 164,430,000
 

Frequently Asked Questions for Innovus Pharmaceuticals (OTCMKTS:INNV)

What is Innovus Pharmaceuticals' stock symbol?

Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."

How were Innovus Pharmaceuticals' earnings last quarter?

Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.01) EPS for the quarter. The firm earned $2.22 million during the quarter. Innovus Pharmaceuticals had a negative net margin of 102.95% and a negative return on equity of 330.39%. View Innovus Pharmaceuticals' Earnings History.

Who are some of Innovus Pharmaceuticals' key competitors?

Who are Innovus Pharmaceuticals' key executives?

Innovus Pharmaceuticals' management team includes the folowing people:

  • Henry J. Esber Ph.D., Chairman of the Board (Age 78)
  • Bassam B. Damaj Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Rauly Gutierrez CPA, Principal Financial Officer, Principal Accounting Officer
  • Randy J. Berholtz Esq. J.D., Executive Vice President, General Counsel, Secretary (Age 53)
  • Vivian H. Liu, Director (Age 55)
  • Ziad Mirza M.D., Director (Age 54)

How do I buy Innovus Pharmaceuticals stock?

Shares of Innovus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innovus Pharmaceuticals' stock price today?

One share of Innovus Pharmaceuticals stock can currently be purchased for approximately $0.10.

How big of a company is Innovus Pharmaceuticals?

Innovus Pharmaceuticals has a market capitalization of $14.39 million and generates $4.82 million in revenue each year. The company earns $-13,700,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Innovus Pharmaceuticals employs 5 workers across the globe.

How can I contact Innovus Pharmaceuticals?

Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92122. The company can be reached via phone at 858-964-5123 or via email at [email protected]


MarketBeat Community Rating for Innovus Pharmaceuticals (OTCMKTS INNV)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  86
MarketBeat's community ratings are surveys of what our community members think about Innovus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Innovus Pharmaceuticals (OTCMKTS:INNV)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Innovus Pharmaceuticals (OTCMKTS:INNV)

Price Target History for Innovus Pharmaceuticals (OTCMKTS:INNV)

Analysts' Ratings History for Innovus Pharmaceuticals (OTCMKTS:INNV)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History and Estimates Chart for Innovus Pharmaceuticals (OTCMKTS:INNV)

Earnings by Quarter for Innovus Pharmaceuticals (OTCMKTS:INNV)

Earnings History by Quarter for Innovus Pharmaceuticals (OTCMKTS INNV)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.01)$2.22 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.01)$2.04 millionViewN/AView Earnings Details
3/6/2017Q4 2016($0.02)$1.69 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.01)$1.88 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Innovus Pharmaceuticals (OTCMKTS:INNV)
Current Year EPS Consensus Estimate: $-0.06 EPS

Dividends

Dividend History for Innovus Pharmaceuticals (OTCMKTS:INNV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Innovus Pharmaceuticals (OTCMKTS INNV)

Insider Ownership Percentage: 19.14%
Insider Trades by Quarter for Innovus Pharmaceuticals (OTCMKTS:INNV)

Insider Trades by Quarter for Innovus Pharmaceuticals (OTCMKTS INNV)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2013Bassam DamajCEOBuy416,841$0.32$133,389.12View SEC Filing  
2/2/2013Bassam DamajCEOBuy250,406$0.48$120,194.88View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Innovus Pharmaceuticals (OTCMKTS INNV)

Source:

Social Media

Financials

Chart

Innovus Pharmaceuticals (OTCMKTS INNV) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.